98%
921
2 minutes
20
To address the unmet need for a widely available examination for mortality prediction, this study developed a foundation visual artificial intelligence (VAI) to enhance mortality risk stratification using chest X-rays (CXRs). The VAI employed deep learning to extract CXR features and a Cox proportional hazard model to generate a hazard score ("CXR-risk"). We retrospectively collected CXRs from patients visited outpatient department and physical examination center. Subsequently, we reviewed mortality and morbidity outcomes from electronic medical records. The dataset consisted of 41,945, 10,492, 31,707, and 4441 patients in the training, validation, internal test, and external test sets, respectively. During the median follow-up of 3.2 (IQR, 1.2-6.1) years of both internal and external test sets, the "CXR-risk" demonstrated C-indexes of 0.859 (95% confidence interval (CI), 0.851-0.867) and 0.870 (95% CI, 0.844-0.896), respectively. Patients with high "CXR-risk," above 85th percentile, had a significantly higher risk of mortality than those with low risk, below 50th percentile. The addition of clinical and laboratory data and radiographic report further improved the predictive accuracy, resulting in C-indexes of 0.888 and 0.900. The VAI can provide accurate predictions of mortality and morbidity outcomes using just a single CXR, and it can complement other risk prediction indicators to assist physicians in assessing patient risk more effectively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092331 | PMC |
http://dx.doi.org/10.1007/s10278-024-01247-y | DOI Listing |
Diagn Pathol
September 2025
Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Background: Gastric cancer is one of the most common cancers worldwide, with its prognosis influenced by factors such as tumor clinical stage, histological type, and the patient's overall health. Recent studies highlight the critical role of lymphatic endothelial cells (LECs) in the tumor microenvironment. Perturbations in LEC function in gastric cancer, marked by aberrant activation or damage, disrupt lymphatic fluid dynamics and impede immune cell infiltration, thereby modulating tumor progression and patient prognosis.
View Article and Find Full Text PDFImmun Ageing
September 2025
Department of Biomedical Data Sciences, Molecular Epidemiology, LUMC, Leiden, The Netherlands.
The MetaboHealth score is an indicator of physiological frailty in middle aged and older individuals. The aim of the current study was to explore which molecular pathways co-vary with the MetaboHealth score. Using a Luminex cytokine assay and liquid chromatography-mass spectrometry-based proteomics we explored the plasma proteins associating with the difference in 100 extreme scoring individuals selected from two large population cohorts, the Leiden Longevity Study (LLS) and the Rotterdam Study (RS), and discordant monozygotic twin pairs from the Netherlands Twin Register (NTR).
View Article and Find Full Text PDFBMC Infect Dis
September 2025
Department of Laboratory Medicine, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China.
Background: Serratia marcescens is an opportunistic pathogen increasingly associated with healthcare-associated infections and rising antimicrobial resistance. The emergence of multidrug-resistant (MDR) and carbapenem-resistant S. marcescens (CRSM) presents significant therapeutic challenges.
View Article and Find Full Text PDFRen Fail
December 2025
Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
The Grams model, designed to predict adverse event risks in advanced chronic kidney disease (CKD) patients, was evaluated in a Chinese cohort of 1,333 patients with eGFR below 30 mL/min/1.73 m. The model demonstrated moderate to good discrimination across outcomes, performing well in predicting kidney replacement therapy (KRT) but overestimating the risks of cardiovascular disease (CVD) and mortality.
View Article and Find Full Text PDFAnaesthesiologie
September 2025
Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Sodium-glucose Cotransporter 2 (SGLT-2) inhibitors are oral antidiabetic drugs that were developed for the treatment of patients with diabetes mellitus and are now also approved for treating chronic heart failure and chronic kidney disease. By inhibiting SGLT‑2 in the proximal renal tubule, urinary excretion of glucose is increased. Large randomized trials have demonstrated improved glycemic control, reduced cardiovascular events and lower mortality but also an increased risk of urogenital infections and dehydration.
View Article and Find Full Text PDF